Work

Abstract LB-194: First-in-human Phase I study of the CD40 agonist mAb CDX-1140 and in combination with CDX-301 (rhFLT3L) in patients with advanced cancers: Interim results

Year: 2019

Type: conference-abstract

Source: Immunology

DOI: 10.1158/1538-7445.sabcs18-lb-194

Authors: Rachel E. Sanborn, Nashat Y. Gabrail, Nina Bhardwaj, Michael S. Gordon, Mark O'Hara, Danny Khalil, Thomas Hawthorne, Richard Gedrich, Laura Vitale, Mark Rogalski, Tianshu Li, Tracey Rawls, Tibor Keler, Michael Yellin

Institutions: Providence Portland Medical Center, Gabrail Cancer Center, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, HonorHealth, Hospital of the University of Pennsylvania, Memorial Sloan Kettering Cancer Center, Celldex Therapeutics (United States)

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4248064586

Cites:

Cited by:

Related to: 10